Anzeige
Mehr »
Samstag, 17.01.2026 - Börsentäglich über 12.000 News
Unabhängiger Analyst sieht bei dieser Goldaktie über +200% Kurspotenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0DLB7 | ISIN: CA88337V1004 | Ticker-Symbol: TTX
Frankfurt
16.01.26 | 12:44
0,184 Euro
+21,85 % +0,033
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
THERALASE TECHNOLOGIES INC Chart 1 Jahr
5-Tage-Chart
THERALASE TECHNOLOGIES INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,1520,18516.01.

Aktuelle News zur THERALASE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoTheralase Technologies Inc: Theralase, Ferring sign clinical development agreement10
MoXFRA TTX: WIEDERAUFNAHME/RESUMPTION108FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
MoTheralase and Ferring ink deal for new bladder cancer study7
THERALASE Aktie jetzt für 0€ handeln
MoTheralase Technologies Inc.: Ferring Pharmaceuticals and Theralase(R) Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer156The collaborative clinical study will evaluate ADSTILADRIN (nadofaragene firadenovec-vncg) in combination with the investigational drug Ruvidar (TLD-1433) in patients with Bacillus Calmette-Guérin-unresponsive...
► Artikel lesen
MoXFRA TTX: AUSSETZUNG/SUSPENSION268DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILTHERALASE TECHNOLOGIE.INC...
► Artikel lesen
09.01.Theralase Technologies Inc: Theralase 7,850,882-share private placement11
24.12.25Theralase Technologies Inc: Theralase Technologies closes $1.33-million financing1
23.12.25Theralase(R) closes $1.3M non-brokered private placement2
23.12.25Theralase raises C$1.33 million in private placement for cancer study2
23.12.25Theralase Technologies Inc.: Theralase(R) Closes $1.3 M Non-Brokered Private Placement252Toronto, Ontario--(Newsfile Corp. - December 23, 2025) - Theralase Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase" or the "Company"), a clinical stage pharmaceutical company pioneering...
► Artikel lesen
12.12.25Theralase Technologies Inc: Theralase cancels $4.5M placement, arranges placement1
12.12.25Theralase commences C$ 2M non-brokered private placement2
12.12.25Theralase announces $2 million private placement offering1
12.12.25Theralase Technologies Inc.: Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing405Toronto, Ontario--(Newsfile Corp. - December 12, 2025) - Theralase Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase" or the "Company"), a clinical stage pharmaceutical company pioneering light...
► Artikel lesen
24.11.25Theralase Technologies Inc.: Theralase(R) Announces Brokered LIFE Financing to Further Advance its Phase II Non-Muscle Invasive Bladder Cancer Clinical Study182Toronto, Ontario--(Newsfile Corp. - November 24, 2025) - Theralase Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase" or the "Company"), a clinical stage pharmaceutical company pioneering light...
► Artikel lesen
17.11.25Theralase Technologies Inc: Theralase to host conference call Nov. 192
17.11.25Theralase Technologies Inc.: Theralase(R) Investor Conference Call Reminder204Toronto, Ontario--(Newsfile Corp. - November 17, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical pioneering light, radiation...
► Artikel lesen
11.11.25Theralase Technologies Inc: Theralase Technologies loses $3.43-million in Q34
10.11.25Theralase Technologies Inc.: Theralase(R) Releases 3Q2025 Financial Statements351Toronto, Ontario--(Newsfile Corp. - November 10, 2025) - Theralase® Technologies Inc. (TSXV:TLT) (OTCQB:TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical pioneering light, radiation...
► Artikel lesen
06.11.25Buzz on the Bullboards: Baytex, Theralase, and Bombardier drive investor buzz this week7
Weiter >>
52 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1